Evidence map›Paper›PMID 37966116›Full record

ReviewThe Journal of clinical investigation2023

Recent advances in lung organoid development and applications in disease modeling.

Ana I Vazquez-Armendariz, Purushothama Rao Tata

Open access · goldAbstract readReview
In one paragraph

Review in The Journal of clinical investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
27.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 105 citations in OpenAlex.

  1. Review
  2. Preclinical models of COPD: a state of the art review.The European respiratory journal · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Long isoforms of the COPD risk gene FAM13A orchestrate human lung epithelial development.American journal of respiratory cell and molecular biology · 2026
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Ana I Vazquez-ArmendarizUniversity of Bonn, Transdisciplinary Research Area Life and Health, Organoid Biology, Life & Medical Sciences Institute, Bonn, Germany.
Purushothama Rao TataDepartment of Cell Biology, Duke University School of Medicine, Durham, North Carolina, USA.
Duke University · USUniversity of Bonn · DE

Funding

Molecular control of a novel transitional cell state in alveolar regenerationR01HL153375 · NHLBI · DUKE UNIVERSITY · PI Purushothama Rao Tata · 2020 to 2026
$3.4M
Cellular crosstalk and molecular mechanisms in the initiation and progression of pulmonary fibrosisR01HL160939 · NHLBI · DUKE UNIVERSITY · PI TATA, PURUSHOTHAMA RAO · 2022 to 2025
$2.1M
Mechanisms of submucosal gland cell mediated airway regenerationR01HL146557 · NHLBI · DUKE UNIVERSITY · PI TATA, PURUSHOTHAMA RAO · 2019 to 2023
$2.0M
To define the role of SOX9 and Sox9+ cells in alveolar homeostasis and regenerationR00HL127181 · NHLBI · DUKE UNIVERSITY · PI TATA, PURUSHOTHAMA RAO · 2017 to 2019
$738k
NHLBI NIH HHS R00 HL127181NHLBI NIH HHS R01 HL146557NHLBI NIH HHS R01 HL153375NHLBI NIH HHS R01 HL160939
6 · The paper itself

Abstract

Over the last decade, several organoid models have evolved to acquire increasing cellular, structural, and functional complexity. Advanced lung organoid platforms derived from various sources, including adult, fetal, and induced pluripotent stem cells, have now been generated, which more closely mimic the cellular architecture found within the airways and alveoli. In this regard, the establishment of novel protocols with optimized stem cell isolation and culture conditions has given rise to an array of models able to study key cellular and molecular players involved in lung injury and repair. In addition, introduction of other nonepithelial cellular components, such as immune, mesenchymal, and endothelial cells, and employment of novel precision gene editing tools have further broadened the range of applications for these systems by providing a microenvironment and/or phenotype closer to the desired in vivo scenario. Thus, these developments in organoid technology have enhanced our ability to model various aspects of lung biology, including pathogenesis of diseases such as chronic obstructive pulmonary disease, pulmonary fibrosis, cystic fibrosis, and infectious disease and host-microbe interactions, in ways that are often difficult to undertake using only in vivo models. In this Review, we summarize the latest developments in lung organoid technology and their applicability for disease modeling and outline their strengths, drawbacks, and potential avenues for future development.

Indexed as

Induced Pluripotent Stem CellsPluripotent Stem CellsEndothelial CellsLungOrganoids

Identifiers

PMID37966116
PMCPMC10645385
OpenAlexW4388698725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.